Finding chemo: the search for marine-based pharmaceutical drugs active against cancer

Clinical Status of Anti-Cancer Agents Derived from Marine Sources

(2013) Ram Singh et al.   Anti-Cancer Agents in Medicinal Chemistry

First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours

(2012) T A Yap et al.   BRITISH JOURNAL OF CANCER

Dolastatin 15, a mollusk linear peptide, and Celecoxib, a selective cyclooxygenase-2 inhibitor, prevent preneoplastic colonic lesions and induce apoptosis through inhibition of the regulatory transcription factor NF-κB and an inflammatory protein, iNOS

(2012) Honit Piplani et al.   EUROPEAN JOURNAL OF CANCER PREVENTION

Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy

(2012) Libero Santarpia et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors

(2012) Christophe Massard et al.   INVESTIGATIONAL NEW DRUGS

Up-regulation of p53 and mitochondrial signaling pathway in apoptosis by a combination of cox-2 inhibitor, celecoxib and dolastatin 15, a marine mollusk linear peptide in experimental colon carcinogenesis

(2012) Honit Piplani et al.   MOLECULAR CARCINOGENESIS

Pachastrissamine fromPachastrissa sp. Inhibits Melanoma Cell Growth by Dual Inhibition of Cdk2 and ERK-mediated FOXO3 Downregulation

(2012) Hyun Yoo et al.   PHYTOTHERAPY RESEARCH

Caspase 2 Activation and ER Stress Drive Rapid Jurkat Cell Apoptosis by Clofibrate

(2012) Fabio Penna et al.   PLoS One

The retinoblastoma family of proteins and their regulatory functions in the mammalian cell division cycle

(2012) Shauna A Henley et al.   Cell Division

Cell death pathology: The war against cancer

(2011) Alessandro Rufini et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Pachastrissamine (jaspine B) and its stereoisomers inhibit sphingosine kinases and atypical protein kinase C

(2011) Yuji Yoshimitsu et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Bio-mining the microbial treasures of the ocean: New natural products

(2011) Johannes F. Imhoff et al.   BIOTECHNOLOGY ADVANCES

Gold from the sea: Marine compounds as inhibitors of the hallmarks of cancer

(2011) Marc Schumacher et al.   BIOTECHNOLOGY ADVANCES

The marine sponge toxin agelasine B increases the intracellular Ca2+ concentration and induces apoptosis in human breast cancer cells (MCF-7)

(2011) Adriana A. Pimentel et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Targeting p53 as a therapeutic strategy in sensitizing TRAIL-induced apoptosis in cancer cells

(2011) Jing Zhao et al.   CANCER LETTERS

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Caspases and cancer

(2011) M Olsson et al.   CELL DEATH AND DIFFERENTIATION

Specific and prolonged proteasome inhibition dictates apoptosis induction by marizomib and its analogs

(2011) Claudia P. Miller et al.   CHEMICO-BIOLOGICAL INTERACTIONS

From the Sea to Anticancer Therapy

(2011) P. Russo et al.   CURRENT MEDICINAL CHEMISTRY

The Molecular Machinery Regulating Apoptosis Signal Transduction and its Implication in Human Physiology and Pathophysiologies

(2011) C. T. Hellwig et al.   CURRENT MOLECULAR MEDICINE

Fascaplysin exert anti-tumor effects through apoptotic and anti-angiogenesis pathways in sarcoma mice model

(2011) Xiaojun Yan et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response

(2011) E. Colado et al.   HAEMATOLOGICA

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination

(2011) Michael Millward et al.   INVESTIGATIONAL NEW DRUGS

The cell cycle and cancer

(2011) Gareth H Williams et al.   JOURNAL OF PATHOLOGY

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

(2011) Javier Cortes et al.   LANCET

Role of Bcl-2 family proteins and caspases in the regulation of apoptosis

(2011) Mohammad Shamsul Ola et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Cytarabine Dose for Acute Myeloid Leukemia

(2011) Bob Löwenberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

The marine alkaloid naamidine A promotes caspase-dependent apoptosis in tumor cells

(2010) Daniel V. LaBarbera et al.   ANTI-CANCER DRUGS

Inhibition of mitochondrial respiration mediates apoptosis induced by the anti-tumoral alkaloid lamellarin D

(2010) Caroline Ballot et al.   APOPTOSIS

Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model

(2010) Ajita V. Singh et al.   BRITISH JOURNAL OF HAEMATOLOGY

Targeting the hallmarks of cancer

(2010) Aisha Siddiqa et al.   CANCER BIOLOGY & THERAPY

Fucoxanthin and its deacetylated product, fucoxanthinol, induce apoptosis of primary effusion lymphomas

(2010) Kei Yamamoto et al.   CANCER LETTERS

Targeting apoptosis pathways by natural compounds in cancer: Marine compounds as lead structures and chemical tools for cancer therapy

(2010) Karin von Schwarzenberg et al.   CANCER LETTERS

Mitochondrial control of caspase-dependent and -independent cell death

(2010) Ludivine A. Pradelli et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Kinases as targets in the treatment of solid tumors

(2010) Georgios Giamas et al.   CELLULAR SIGNALLING

Phase III Trials of Eribulin Mesylate (E7389) in Extensively Pretreated Patients With Locally Recurrent or Metastatic Breast Cancer

(2010) Chris Twelves et al.   Clinical Breast Cancer

Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma

(2010) M. V. Mateos et al.   CLINICAL CANCER RESEARCH

Phase I and Pharmacokinetic Study of Sequential Paclitaxel and Trabectedin Every 2 Weeks in Patients with Advanced Solid Tumors

(2010) Q. Chu et al.   CLINICAL CANCER RESEARCH

Targeting Cellular Proapoptotic Molecules for Developing Anticancer Agents from Marine Sources

(2010) Xiukun Lin et al.   CURRENT DRUG TARGETS

Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine

(2010) Javier Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Cryptosphaerolide, a Cytotoxic Mcl-1 Inhibitor from a Marine-Derived Ascomycete Related to the GenusCryptosphaeria

(2010) Hyuncheol Oh et al.   JOURNAL OF NATURAL PRODUCTS

Cancer, chitosan nanoparticles and catalytic nucleic acids

(2010) Mei Lin Tan et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

The deacetylase inhibitor LAQ824 induces notch signalling in haematopoietic progenitor cells

(2010) Kerstin Schwarz et al.   LEUKEMIA RESEARCH

Generating a Generation of Proteasome Inhibitors: From Microbial Fermentation to Total Synthesis of Salinosporamide A (Marizomib) and Other Salinosporamides

(2010) Barbara C. Potts et al.   Marine Drugs

Neuroprotective Properties of Chitosan and Its Derivatives

(2010) Ratih Pangestuti et al.   Marine Drugs

A Review of Trabectedin (ET-743): A Unique Mechanism of Action

(2010) Maurizio D'Incalci et al.   MOLECULAR CANCER THERAPEUTICS

Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives

(2010) Bruno Vincenzi et al.   PHARMACOGENOMICS

Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant

(2009) Paul M. Barr et al.   AMERICAN JOURNAL OF HEMATOLOGY

Molecular pharmacology and antitumor activity of Zalypsis ® in several human cancer cell lines

(2009) Juan F.M. Leal et al.   BIOCHEMICAL PHARMACOLOGY

The natural marine anhydrophytosphingosine, Jaspine B, induces apoptosis in melanoma cells by interfering with ceramide metabolism

(2009) Yahya Salma et al.   BIOCHEMICAL PHARMACOLOGY

Heteronemin, a spongean sesterterpene, inhibits TNFα-induced NF-κB activation through proteasome inhibition and induces apoptotic cell death

(2009) Marc Schumacher et al.   BIOCHEMICAL PHARMACOLOGY

Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells

(2009) C. P. Miller et al.   BLOOD

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

(2009) S. Goel et al.   CLINICAL CANCER RESEARCH

Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors

(2009) A. R. Tan et al.   CLINICAL CANCER RESEARCH

Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour Infusion Weekly in Patients with Advanced Solid Malignancies

(2009) B. Forouzesh et al.   CLINICAL CANCER RESEARCH

Caspase-Independent Pathways of Programmed Cell Death: The Unraveling of New Targets of Cancer Therapy?

(2009) C. Constantinou et al.   CURRENT CANCER DRUG TARGETS

Differential effects of triterpene glycosides, frondoside A and cucumarioside A2-2 isolated from sea cucumbers on caspase activation and apoptosis of human leukemia cells

(2009) Jun-O Jin et al.   FEBS LETTERS

Induction of apoptosis by phloroglucinol derivative from Ecklonia Cava in MCF-7 human breast cancer cells

(2009) Chang-Suk Kong et al.   FOOD AND CHEMICAL TOXICOLOGY

Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2009) Linda T. Vahdat et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Biweekly Plitidepsin as Second-Line Therapy for Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

(2009) Herlinde Dumez et al.   Marine Drugs

Protein kinase Cε: an oncogene and emerging tumor biomarker

(2009) Michael A Gorin et al.   Molecular Cancer

BH3-only proteins Mcl-1 and Bim as well as endonuclease G are targeted in spongistatin 1-induced apoptosis in breast cancer cells

(2009) U. M. Schneiders et al.   MOLECULAR CANCER THERAPEUTICS

Essential role of mitochondria in apoptosis of cancer cells induced by the marine alkaloid Lamellarin D

(2009) C. Ballot et al.   MOLECULAR CANCER THERAPEUTICS

BH3-only proteins and their roles in programmed cell death

(2009) M Giam et al.   ONCOGENE

Regulation of phosphoinositide 3-kinase expression in health and disease

(2009) Klaartje Kok et al.   TRENDS IN BIOCHEMICAL SCIENCES

Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks

(2008) E. M. Ocio et al.   BLOOD

Role of Smac in cephalostatin-induced cell death

(2008) A Rudy et al.   CELL DEATH AND DIFFERENTIATION

Spongistatin 1: a new chemosensitizing marine compound that degrades XIAP

(2008) L Schyschka et al.   LEUKEMIA

The marine lipopeptide somocystinamide A triggers apoptosis via caspase 8

(2008) W. Wrasidlo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?

(2008) Jerry E. Chipuk et al.   TRENDS IN CELL BIOLOGY